Apatinib Mesylate

甲磺酸阿帕替尼

Report date: 2025/07/08 16:56:58
NME

Base Information

Drug NameApatinib Mesylate
Drug Alias NameRivoceranib阿帕替尼rivoceranib mesylateApartinib艾坦 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[23] 
Global Approved IndicationsStomach Neoplasms
Approved Indications in ChinaStomach Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2014/10/17
Country/TerritoryBelgiumUnited StatesUkraine +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAdvenchen Laboratories Llc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu shengdi Medicine Co LtdElevar Therapeutics IncThe Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School +[6] 
Inactive CompaniesTongji UniversityGuangxi Medical UniversityFujian Medical University +[11] 
Active IndicationsGastroesophageal Junction NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[12] 
Inactive IndicationsMetastatic breast cancerSolid tumoursNasopharyngeal Neoplasms +[11] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBank